Indoco Remedies Ltd. has announced that its Clinical Research Organisation, AnaCipher has received approval from the National Health Surveillance Agency of Brazil (Agência Nacional de Vigilância Sanitária – ANVISA) for both, clinical and bioanalytical facilities. The inspection was conducted from March 30, 2026, to April 7, 2026.

With this approval, the CRO is authorised to conduct Bioavailability & Bioequivalence studies for submission to Brazil, along with associated bioanalytical support in accordance with ANVISA regulatory requirements.

Commenting on this development, Aditi Panandikar, Managing Director, Indoco Remedies Ltd. said, “The approval reflects our CRO’s robust quality management systems, qualified scientific and clinical teams, validated analytical capabilities, and adherence to international regulatory and Good Clinical Practice standards. It reinforces our commitment to global quality standards and enhances our ability to support pharmaceutical companies in conducting studies for Brazil and expanding across Latin America.”

This approval further strengthens AnaCipher’s international regulatory footprint and reinforces its position as a trusted partner for global clinical research programmes.

AnaCipher is a clinical research organisation headquartered in Hyderabad, India. The CRO provides bioequivalence and bioavailability studies, bioanalysis, clinical operations, regulatory affairs, data management, and biostatistics services to pharmaceutical companies worldwide.

The CRO has been accredited by CDSCO, USFDA, WHO, EMA, UKMHRA, MoH-Oman &  project based approvals have been received from TPD-Canada, NMPA - China, MCC-South Africa & MoH-Iraq.